SPRO
Spero Therapeutics Accelerates Growth with Landmark FDA Approval and Strategic Partnerships
Spero Therapeutics has made significant strides in the second quarter of 2026, with a series of major milestones that underscore its commitment to advancing innovative treatments for patients. On June 17th, the US Food and Drug Administration (FDA) approved Utebzi, the first and only oral carbapenem for the treatment of